CG Oncology (CGON) Cash & Equivalents (2023 - 2026)

CG Oncology has reported Cash & Equivalents for 4 years, with the latest figure at $33.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 18.74% year-over-year to $33.7 million; the trailing twelve-month figure through Mar 2026 stood at $33.7 million (down 18.74% YoY), and the FY2025 full-year result was $32.5 million, down 87.36% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $33.7 million, up from $32.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $257.1 million in Q4 2024, with the low at $8.3 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $57.9 million across 4 years, with a median of $37.6 million in 2025.
• Annual changes were most pronounced in 2024 — Cash & Equivalents surged 3009.94% — and 2025, when it sank 87.36%.
• CG Oncology's Cash & Equivalents stood at $8.3 million in 2023, then surged by 3009.94% to $257.1 million in 2024, then slumped by 87.36% to $32.5 million in 2025, then grew by 3.72% to $33.7 million in 2026.
• The last three Cash & Equivalents figures came in at $33.7 million (Q1 2026), $32.5 million (Q4 2025), and $45.1 million (Q3 2025), per Business Quant data.